795 completed, 205 unknown, 185 recruiting, 183 terminated. 805 Phase 2, 431 Phase 3, 279 Phase 1, 188 Phase 4, 92 Not applicable.
Follow Prednisone: new trials by email Literature Review of Prednisone trials Research Report on Prednisone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT) Prednisone, Ajovy, Manual Therapy - Cranial Nerve Injury, Oropharyngeal Cancer | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 48 | 2027-03-01 | 2026-09-21 |
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients Biospecimen Collection, Computed Tomography, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 20 | 2026-12-08 | 2026-07-20 |
| ACT4RHD is an Open-label, Randomised, Adaptive Platform Trial to Evaluate Novel and Repurposed Clinical Interventions for Patients With Acute Rheumatic Fever and Carditis. ACT4RHD Seeks to Determine Whether These Interventions Reduce RHD Severity at 6 Months. Hydroxychloroquine (HCQ), No Hydroxychloroquine (HCQ), Prednisone or Prednisolone - Rheumatic Fever, Rheumatic Heart Disease in Children | Phase 3 | Not yet recruiting | Starship Child Health, Te Toka Tumai Auckland | 600 | 2026-12-01 | 2026-10-07 |
| Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma Cemiplimab, Prednisone, Sirolimus - Kidney Transplant Recipient, Cutaneous Squamous Cell Carcinoma (CSCC) | Phase 2 | Not yet recruiting | Washington University School of Medicine | 22 | 2026-11-30 | 2026-10-15 |
| Evaluation of the Efficacy and Safety of Compound Betamethasone in Pulmonary Sarcoidosis Prednisone, Compound betamethasone - Sarcoidosis, Pulmonary | Phase 2 / Phase 3 | Not yet recruiting | Peking Union Medical College Hospital | 126 | 2026-11-01 | 2026-10-15 |
| Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants Azithromycin 250 mg x3/week (3 tablets/week), Prednisone 10 mg/day, Hydroxychloroquine 400 mg/day - Interstitial Lung Disease | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 30 | 2026-11-01 | 2026-09-22 |
| Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma Biospecimen Collection, Cisplatin, Computed Tomography - Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 16 | 2026-10-30 | 2026-09-03 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Ivarmacitinib Versus Glucocorticoids in Mild-to-Moderate Systemic Lupus Erythematosus Ivarmacitinib Sulfate Tablets, Prednisone Acetate Tablets - Systemic Lupus Erthematosus | Phase 2 / Phase 3 | Not yet recruiting | Chinese SLE Treatment And Research Group | 294 | 2026-10-15 | 2026-09-11 |
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 15 | 2026-10-09 | 2026-08-13 |
| Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Adult Burkitt Lymphoma | Phase 2 | Not yet recruiting | AIDS Malignancy Consortium | 43 | 2026-09-17 | 2026-10-16 |
| Infliximab for Immune Checkpoint Inhibitor Associated AKI Infliximab, Prednisone, prednisone (oral) - Acute Kidney Injury, Acute Interstitial Nephritis | Phase 4 | Recruiting | Massachusetts General Hospital | 44 | 2026-09-15 | 2026-10-09 |
| A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302] Risvutatug rezetecan (Ris-Rez), Enzalutamide, Abiraterone - Neoplasms, Prostate | Phase 3 | Recruiting | GlaxoSmithKline | 684 | 2026-09-01 | 2026-10-02 |
| Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) Birelentinib, Rituximab, Cyclophosphamid - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 / Phase 3 | Not yet recruiting | Dizal Pharmaceuticals | 880 | 2026-09-01 | 2026-08-05 |
| A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma BL-M08D1, Rituximab, Gemcitabine Hydrochloride - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 204 | 2026-09-01 | 2026-09-14 |
| Tripterygium Wilfordii Plus Prednisone for Active IgG4-Related Disease Prednisone, tripterygium wilfordii - IgG4 Related Disease | Phase 2 | Not yet recruiting | Peking Union Medical College Hospital | 74 | 2026-09-01 | 2026-10-16 |
| Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer Androgen Deprivation Therapy (ADT), Abiraterone, Prednisone - Prostate Cancer | Phase 2 | Recruiting | University of Nebraska | 140 | 2026-09-01 | 2026-10-19 |
| The CARDIOPROTECT Trial Dexrazoxane, Dexrazoxane placebo, Doxorubicin - Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity | Phase 2 | Recruiting | Beth Israel Deaconess Medical Center | 60 | 2026-08-31 | 2026-07-27 |
| Biomarker-Guided Mycophenolate Mofetil Elimination in Low-Risk Older Adult Kidney Transplant Recipients Tacrolimus (Kidney transplant maintenance immunosuppression), Mycophenoate Mofetil, Prednisone (SOC arm) - Kidney Transplant Recipient | Early Phase 1 | Not yet recruiting | Virginia Commonwealth University | 20 | 2026-08-31 | 2026-09-08 |
Showing 20 of 1648. Sign in to see all of them.
Prostatic Neoplasms (246) · Lymphoma (179) · Lymphoma, Large B-Cell, Diffuse (177) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (88) · Lymphoma, Follicular (81) · Lymphoma, Non-Hodgkin (75) · Burkitt Lymphoma (68) · Multiple Myeloma (64) · Leukemia (58) · Hodgkin Disease (45) · Lymphoma, Mantle-Cell (41) · Neoplasms (35) · Lymphoma, T-Cell, Peripheral (33) · Lymphoma, B-Cell (30) · Lymphoma, B-Cell, Marginal Zone (28)
National Cancer Institute (NCI) (83) · M.D. Anderson Cancer Center (50) · Children's Oncology Group (34) · Janssen Research & Development, LLC (34) · Hoffmann-La Roche (30) · National Institute of Allergy and Infectious Diseases (NIAID) (27) · Merck Sharp & Dohme LLC (24) · SWOG Cancer Research Network (24) · Sanofi (20) · Assistance Publique - Hôpitaux de Paris (19) · Ruijin Hospital (17) · Dana-Farber Cancer Institute (16) · Mayo Clinic (16) · Memorial Sloan Kettering Cancer Center (16) · University of Washington (15)
United States (914) · China (298) · Canada (221) · France (213) · Italy (194) · Spain (194) · Germany (173) · United Kingdom (170) · Australia (162) · Belgium (122) · Poland (117) · Netherlands (104) · Israel (91) · Czechia (85) · Brazil (81)
Oliver W. Press, MD, PhD (6) · Christopher J Melani, M.D. (5) · Sandra J. Horning, MD (5)
PMID 37505794, PMID 41671463, PMID 24722180, PMID 40135712, PMID 29272162, PMID 39121442, PMID 39319495, PMID 24970932, PMID 31221778, PMID 33693991, PMID 35230699, PMID 35882475, PMID 38446568, PMID 38864363, PMID 39058968, PMID 40016438, PMID 42020286, PMID 11807147, PMID 16105981, PMID 16407509, PMID 16421426, PMID 16754935, PMID 17654614, PMID 19433688, PMID 19546402, PMID 20007997, PMID 20032498, PMID 20154213, PMID 20600032, PMID 20661232, PMID 21719599, PMID 22337718, PMID 22747660, PMID 23228299, PMID 24224624, PMID 24344215, PMID 24687837, PMID 24787968, PMID 25135998, PMID 25685162, PMID 25829400, PMID 26031410, PMID 26248505, PMID 26609008, PMID 26867033, PMID 26888258, PMID 26913693, PMID 27282998, PMID 28426849, PMID 29148893
2023 (31), U10CA032102 (25), U10CA098543 (19), U10CA180886 (16), 2017 (14), U10CA021115 (13), 2009 (12), 2016 (10), 2015 (9), 2025 (9), U10CA031946 (9), U10CA180888 (9), 2019 (8), U10CA180820 (8), 2014 (7)